NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

MU

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

MU

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

MU

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

MU

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

MU

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

Search

Clarivate PLC

Открыт

СекторТехнологии

2.44 -0.81

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.42

Макс.

2.6

Ключевые показатели

By Trading Economics

Доход

233M

204M

Продажи

-6.1M

617M

Прибыль на акцию

0.2

Рентабельность продаж

33.096

Сотрудники

12,000

EBITDA

-5.3M

231M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+36.76% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

28 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

421M

1.6B

Предыдущая цена открытия

3.25

Предыдущая цена закрытия

2.44

Новостные настроения

By Acuity

29%

71%

78 / 375 Рейтинг в Technology

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Clarivate PLC График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 мар. 2026 г., 23:31 UTC

Популярные акции

Stocks to Watch: Nike, RH, NCino

31 мар. 2026 г., 22:35 UTC

Отчет

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 апр. 2026 г., 00:00 UTC

Приобретения, слияния, поглощения

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 мар. 2026 г., 23:50 UTC

Приобретения, слияния, поглощения

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 мар. 2026 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 мар. 2026 г., 23:33 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 мар. 2026 г., 23:21 UTC

Отчет

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 мар. 2026 г., 23:14 UTC

Обсуждения рынка
Отчет

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 мар. 2026 г., 23:12 UTC

Обсуждения рынка

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss Widens >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 мар. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 мар. 2026 г., 21:36 UTC

Обсуждения рынка

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 мар. 2026 г., 21:33 UTC

Отчет

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 мар. 2026 г., 21:32 UTC

Отчет

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 мар. 2026 г., 21:28 UTC

Отчет

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 мар. 2026 г., 21:26 UTC

Отчет

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 мар. 2026 г., 21:25 UTC

Отчет

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 мар. 2026 г., 21:24 UTC

Обсуждения рынка
Отчет

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 мар. 2026 г., 21:22 UTC

Отчет

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 мар. 2026 г., 21:22 UTC

Отчет

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 мар. 2026 г., 21:21 UTC

Отчет

Nike's Digital Channel Still Too Promotional, CFO Says

31 мар. 2026 г., 21:20 UTC

Отчет

Nike CEO: Converse Remains Important to Portfolio

Сравнение c конкурентами

Изменение цены

Clarivate PLC Прогноз

Целевая цена

By TipRanks

36.76% рост

Прогноз на 12 месяцев

Средняя 3.46 USD  36.76%

Максимум 6 USD

Минимум 2.4 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Clarivate PLC на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

6 ratings

1

Покупка

4

Удержание

1

Продажа

Техническая оценка

By Trading Central

4.2845 / 4.395Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

78 / 375Рейтинг в Технологии

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Clarivate PLC

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.
help-icon Live chat